PMID- 38102670
OWN - NLM
STAT- MEDLINE
DCOM- 20231218
LR  - 20240226
IS  - 1478-6362 (Electronic)
IS  - 1478-6354 (Print)
IS  - 1478-6354 (Linking)
VI  - 25
IP  - 1
DP  - 2023 Dec 15
TI  - Clinical implications of peripheral eosinophil count at diagnosis in patients 
      newly diagnosed with microscopic polyangiitis and granulomatosis with 
      polyangiitis.
PG  - 245
LID - 10.1186/s13075-023-03233-1 [doi]
LID - 245
AB  - BACKGROUND: This study investigated the clinical implications of peripheral 
      eosinophil count at diagnosis in estimating cross-sectional antineutrophil 
      cytoplasmic antibody-associated vasculitis (AAV) activity and predicting 
      all-cause mortality during follow-up in patients newly diagnosed with microscopic 
      polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). METHODS: This 
      study included 224 immunosuppressive drug-naive patients with peripheral 
      eosinophil count at diagnosis < 1,000/mm(3). The Birmingham Vasculitis Activity 
      Score (BVAS), the Five-Factor Score (FFS), erythrocyte sedimentation rate (ESR) 
      and C-reactive protein (CRP) at diagnosis were assessed. RESULTS: The median age 
      of the 224 patients (152 MPA and 72 GPA) was 62.0 years; 35.3% of them were men. 
      At diagnosis, peripheral eosinophil count was significantly correlated with BVAS 
      (P = 0.001), FFS (P = 0.046), ESR (P < 0.001), and CRP (P < 0.001). Deceased 
      patients had a significantly higher median peripheral eosinophil count at 
      diagnosis than surviving patients (310.0/mm(3) vs. 170.0/mm(3), P = 0.004). In 
      addition, patients with MPA and those with cardiovascular and renal 
      manifestations at diagnosis exhibited significantly higher peripheral eosinophil 
      counts than those without. When the optimal cut-off of peripheral eosinophil 
      count at diagnosis for all-cause mortality during follow-up was set at 
      175.0/mm(3), Patients with peripheral eosinophil count at diagnosis >/= 175.0/mm(3) 
      exhibited a significantly lower cumulative patients' survival rate than those 
      with peripheral eosinophil count at diagnosis < 175.0/mm(3) (P = 0.008). 
      CONCLUSIONS: This study was the first to demonstrate that peripheral eosinophil 
      count at diagnosis could estimate cross-sectional AAV activity at diagnosis and 
      contribute to predicting all-cause mortality during follow-up in MPA and GPA 
      patients.
CI  - (c) 2023. The Author(s).
FAU - Ha, Jang Woo
AU  - Ha JW
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Republic of Korea.
FAU - Ahn, Sung Soo
AU  - Ahn SS
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Republic of Korea.
FAU - Song, Jason Jungsik
AU  - Song JJ
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Republic of Korea.
AD  - Institute for Immunology and Immunological Diseases, Yonsei University College of 
      Medicine, Seoul, Republic of Korea.
FAU - Park, Yong-Beom
AU  - Park YB
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Republic of Korea.
AD  - Institute for Immunology and Immunological Diseases, Yonsei University College of 
      Medicine, Seoul, Republic of Korea.
FAU - Lee, Sang-Won
AU  - Lee SW
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Republic of Korea. sangwonlee@yuhs.ac.
AD  - Institute for Immunology and Immunological Diseases, Yonsei University College of 
      Medicine, Seoul, Republic of Korea. sangwonlee@yuhs.ac.
LA  - eng
GR  - 6-2023-0155/a faculty research grant of Yonsei University College of Medicine, 
      Seoul, Republic of Korea/
GR  - NCR 2019-6/CELLTRION PHARM, Inc. Chungcheongbuk-do, Republic of Korea/
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20231215
PL  - England
TA  - Arthritis Res Ther
JT  - Arthritis research & therapy
JID - 101154438
RN  - 0 (Antibodies, Antineutrophil Cytoplasmic)
SB  - IM
MH  - Male
MH  - Humans
MH  - Middle Aged
MH  - Female
MH  - *Microscopic Polyangiitis/diagnosis
MH  - *Granulomatosis with Polyangiitis/diagnosis
MH  - Cross-Sectional Studies
MH  - Eosinophils
MH  - Retrospective Studies
MH  - Antibodies, Antineutrophil Cytoplasmic
MH  - *Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/diagnosis
PMC - PMC10722771
OTO - NOTNLM
OT  - Activity
OT  - Eosinophil
OT  - Granulomatosis with polyangiitis
OT  - Microscopic polyangiitis
OT  - Mortality
COIS- The authors declare no competing interests.
EDAT- 2023/12/16 11:43
MHDA- 2023/12/18 06:42
PMCR- 2023/12/15
CRDT- 2023/12/16 00:01
PHST- 2023/05/15 00:00 [received]
PHST- 2023/12/06 00:00 [accepted]
PHST- 2023/12/18 06:42 [medline]
PHST- 2023/12/16 11:43 [pubmed]
PHST- 2023/12/16 00:01 [entrez]
PHST- 2023/12/15 00:00 [pmc-release]
AID - 10.1186/s13075-023-03233-1 [pii]
AID - 3233 [pii]
AID - 10.1186/s13075-023-03233-1 [doi]
PST - epublish
SO  - Arthritis Res Ther. 2023 Dec 15;25(1):245. doi: 10.1186/s13075-023-03233-1.